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ABSTRACT
Oligonucleotide delivery in vivo is commonly seen
as the principal hurdle to the successful develop-
ment of oligonucleotide drugs. In an analysis of 26
oligonucleotide drugs recently evaluated in late-
stage clinical trials we found that to date at least
half have demonstrated suppression of the target
mRNA and/or protein levels in the relevant cell
types in man, including those present in liver,
muscle, bone marrow, lung, blood and solid
tumors. Overall, this strongly implies that the
drugs are being delivered to the appropriate
disease tissues. Strikingly we also found that the
majority of the drug targets of the oligonucleotides
lie outside of the drugable genome and represent
new mechanisms of action not previously investi-
gated in a clinical setting. Despite the high risk of
failure of novel mechanisms of action in the clinic,
a subset of the targets has been validated by
the drugs. While not wishing to downplay the tech-
nical challenges of oligonucleotide delivery in vivo,
here we demonstrate that target selection and val-
idation are of equal importance for the success of
this field.
INTRODUCTION
Successful drug development is a precarious combination
of the right target, the right drug, the right disease and the
right patient population. When one of these parameters is
ill-chosen the drug fails. As a handful of oligonucleotide
drugs inch toward regulatory approval, consensus accord-
ing to recent reviews and perspectives is that the ‘delivery
problem’ is the pivotal factor which will see this new thera-
peutic paradigm stand or fall (1,2). However, hard
evidence for the failed delivery of a drug in vivo is rarely
available. While not wishing to downplay the technical
challenges of oligonucleotide delivery in vivo, to our view
it plays equal ﬁddle to a parameter that is rarely discussed,
that of target validation.
The pharmaceutical industry considers the optimal drug
target to have a well-understood role in the pathophysi-
ology of the disease, to be disease-modifying when
modulated with drugs, to be non-essential in unaffected
tissues, to have its expression restricted to the disease
tissue, to be assayable with a biomarker to monitor thera-
peutic efﬁcacy and to have a favorable competitive
situation (3). Drug targets can be classiﬁed according
to their clinical validation (4). Validation of a target is
the conﬁrmation of its functional role in the disease
pathology of patients. This is ultimately achieved using
the drug in phase 2 clinical studies. An unvalidated
target represents a new mechanism of action which has
not previously been shown to have therapeutic utility in
patients for a particular indication. Although new
mechanisms of action offer the possibility of breakthrough
treatments, the success rate of drug development
involving unvalidated targets is lower than for validated
targets (5). One analysis gave the probability of success
(ﬁrst dose in patients to approval) for a new mode of
action as 9%, compared with 23% for a drug with an
established mechanism (6). A second report put the
value at 7% (small-molecule drugs; phase 1 to launch)
(7). We have analysed oligonucleotide drugs which have
been recently evaluated in clinical trials with respect to
their target inhibition and their target validation. We
consider downregulation of the target to be an indicator
for successful delivery of the drug to the target tissue.
We identiﬁed 26 oligonucleotide-target combinations
which are, or were until recently, in phase 2 clinical
status or above (Table 1) according to Thomson Reuters
Integrity database. The analysis shows that the targets of
these drugs represent new mechanisms of action and
therefore should be considered high risk. Most of
them fall outside of the drugable genome and thereby
avoid competition from small-molecule drugs for the
same target. In 14 examples suppression of the target
mRNA and/or protein levels strongly implies that the
drugs are being delivered to the appropriate disease
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Table 1. Oligonucleotide drugs recently under active development in phase 2 clinical trials or above (Data are extracted from Thomson Reuters
Integrity database on 3 April 2012)
Target Drug (indication) References to target inhibition
in man
[1] Apolipoprotein B-100 (APOB)
Non-sense or frameshift mutations in the
LDL-receptor binding domain of apoB cause
hypercholesterolemia (OMIM 107730)
Mipomersen (pre-registered: FH)
20-O-MOE ASO administered i.v. or s.c. reduces
target protein and LDL cholesterol in serum
(11–14)
[2] Dystrophin (DMD)
Mutations induce a frame shift or non-sense
residue and produces dysfunctional protein
(OMIM 300377)
Eteplirsen (phase 2: DMD)
Morpholino ASO administered i.v. causes exon
skipping and restores dystrophin levels in
muscle biopsies
(18)
[3] Drisapersen (phase 3: DMD)
20-O-Me ASO administered s.c. causes exon
skipping and restores dystrophin levels in
muscle biopsies of patients
(19)
[4] B cell lymphoma-2 (BCL2)
Inhibitor of cancer cell apoptosis associated with
chemotherapy or radiotherapy resistance
Oblimersen (phase 3: cancer)
Phosphorothioate oligodeoxynucleotide ASO ad-
ministered i.v. continuous infusion inhibits
target levels in PBMCs and bone marrow cells
(24–26)
[5] Survivin (BIRC5)
Inhibitor of cancer cell apoptosis, highly expressed
in tumors associated with chemotherapy or
radiotherapy resistance
ISIS-23722 (phase 2: cancer)
20-O-MOE ASO administered i.v. accumulates in
tumor tissue, suppresses target, restores apop-
tosis in tumor cells
(28)
[6] Clusterin (CLU)
Secreted stress-induced cytoprotective protein,
associated with chemotherapy or radiotherapy
resistance
Custirsen (phase 3: cancers)
20-O-MOE ASO administered i.v. suppresses target
in prostate cancer tissue and in lymph nodes,
increases apoptotic index and improves survival
(32–34)
[7] Heat shock 27 kDa protein 1 (HSPB1)
Chaperone protein associated with chemotherapy
or radiotherapy resistance.
OGX-427 (phase 2: cancer)
20-O-MOE ASO administered i.v. induces changes
in tumor markers, measurable disease and
circulating tumor counts.
(38)
[8] Eukaryotic translation initiation factor 4E (EIF4E)
Protein translation factor
ISIS-EIF4ERx (phase 2: cancer)
20-O-MOE ASO administered i.v. inhibits eIF-4E
mRNA and protein expression, as well as
downstream markers in tumor biopsies.
(40)
[9] Ribonucleoside-diphosphate reductase M2 chain
(RRM2)
Essential protein for synthesis of
deoxyribonucleotides
GTI-2040 (phase 2: cancer)
Phosphorothioate oligodeoxynucleotide ASO ad-
ministered i.v. with cytarabine in AML
patients: reduces RRM2 protein in bone
marrow cells in complete responders and not
in non-responders
(43, 44)
[10] CCR3, beta chain (CCR3, CSF2RB)
Chemokine signaling proteins mediate eosinophil
trafﬁcking in asthma
TPI ASM8 (phase 2: allergic asthma)
Combination of two phosphorothioate oligodeoxy-
nucleotide ASOs targeting CCR3 and the beta
chain suppress target mRNAs when delivered
via nebulizer
(48, 49)
[11] ICAM1 (ICAM1)
Glycoprotein involved in cell trafﬁcking in inﬂam-
matory bowel pathophysiology
Alicaforsen (phase 3: pouchitis)
Phosphorothioate oligodeoxynucleotide ASO ad-
ministered i.v. inhibits ICAM-1 protein expres-
sion in mucosal biopsies
(51)
[12] C-reactive protein (CRP)
Elevated levels of CRP are a biomarker
of inﬂammation
ISIS-CRPRx (phase 2: rheumatoid arthritis)
20-O-MOE ASO reduces levels of CRP by 70% in
healthy volunteers
(http://ir.isispharm.com/phoenix.
zhtml?c=222170&p=irol-news-
Article_pf&ID=1531705;
February 2011)
[13] Transthyretin (TTR)
Mutations induce formation of aggregated protein
deposits (OMIM 176300)
ALN-TTR02 (phase 2: amyloidosis)
SiRNA reduces levels of TTR by up to 94% in
healthy volunteers. LNP formulated
(http://phx.corporate-ir.net/phoe-
nix.zhtml?c=148005&p=
irol-newsArticle_print&I-
D=1714793&highlight; July
2012)
[14] Mir-122 (MIR122) Miravirsen (phase 2: hepatitis C) (56)
(continued)
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tissues. In a few cases the oligonucleotide drugs have
validated their targets.
RESULTS
For this analysis we examined 26 drug/target combinations
(Table 1). Most of the drugs are single-stranded, second
generation antisense oligonucleotides (ASOs). They are
accompanied by ﬁve small interfering RNAs (siRNAs)
and a single anti-microRNA oligonucleotide (AMO).
Most of the ASOs are phosphorothioate oligonucleotides
and many have also been chemically modiﬁed at selected
riboses to enhance their pharmacokinetics (PK) and
pharmacodynamics (PD) properties (Figure 1). First
generation phosphorothioate oligodeoxynucleotides and
second generation oligodeoxynucleotides which are ter-
minally modiﬁed with nuclease-resistant, afﬁnity-
enhancing modiﬁcations induce target mRNA target
cleavage via RNase H-dependent mechanisms. The re-
mainder modulates splicing, inhibits translation or blocks
RNA function (8). To our knowledge none of these drugs
is administered to patients using a special formulation.
The targets of these oligonucleotides come from a range
of protein families which is notably under-represented in
the classical drugable families, i.e. enzymes and receptors.
Of the targets, ﬁve are enzymes and therefore possibly
drugable with small molecules (PTPN1, RRM2, SYK,
RAF1, AKT1). Several are extracellular proteins (APOB,
CLU, CRP, CCR3/CSF2RB, CTGF, VLA-4, ICAM1,
TGFB2, TTR) and therefore potentially drugable with
therapeutic antibodies or proteins. The majority of the
targets was clinically unvalidated at the outset of the
trials and therefore represents a new mechanism of
action for their respective diseases. Three of the
targets—APOB, TTR and DMD—are the products of
genes which are disregulated or non-functional because
of changes in their DNA sequence (e.g. mutations, dele-
tions, translocations, etc.) and which have been proven to
cause disease. Hence, they are ‘genetically validated’.
We highlight below 14 drugs for which inhibition of the
molecular target at either mRNA or protein level in patient
samples has been reported. They are: APOB/mipomersen;
DMD/eteplirsen; DMD/drisapersen; BCL2/oblimersen;
CLU/custirsen; HSPB1/OGX-427; BIRC5/ISIS-23722;
EIF4E/ISIS-EIF4ERx; RRM2/GTI-2040; ICAM1/alica-
forsen; CCR3, CSF2RB/TPI ASM8; CRP/ISIS-CRPRx;
TTR/ALN-TTR02; and MIR122/miravirsen. The
MIR122/miravirsen pair is included although miravirsen
is not expected to repress levels of the microRNA
(miRNA) mir-122. In these 14 cases it can be safely
assumed that the oligonucleotide drug is being delivered
to its cellular target, although it cannot be assumed that
the magnitude of target downregulation is sufﬁcient to
mediate a therapeutic effect.
ApoB/mipomersen for familial hypercholesterolemia
(FH) [1]. The liver-derived apoliprotein B-100 (ApoB)
protein plays a fundamental role in cholesterol homeosta-
sis as a structural component of very low-density lipopro-
tein (VLDL) and as a ligand for LDL receptor-mediated
endocytosis of LDL by liver cells. Its over-production and
decreased clearance are seen in cardiovascular-associated
diseases, as well as inherited diseases such as familial
hypercholesterolemia (FH: OMIM 107730). Familial de-
fective ApoB hypercholesterolemia is a result of non-sense
or frame-shift mutations within the LDL-receptor binding
domain of ApoB and causes severe hypercholesterolemia
and premature cardiovascular disease. Statin drugs are
unable to reduce cholesterol sufﬁciently for these
patients. ApoB is an ideal target for an mRNA-targeting
oligonucleotide in FH (reviewed in (9)). It is a genetically
validated target which is synthesized in the liver, one of
the predominant target tissues of ASOs in man.
Furthermore, the target protein is secreted into the
blood allowing its use as a biomarker to assess directly
drug action. Mipomersen is a subcutaneously delivered
ASO of 20-nucleotide length (20-mer) and modiﬁed
with terminal 20-O-methoxyethyl (MOE)-ribonucleotides.
Table 1. Continued
Target Drug (indication) References to target inhibition
in man
MicroRNA-122 is necessary for translation of
HCV genome
LNA AMO administered s.c. reduces viral RNA
in the blood of HCV patients
[15] TGF-b2 (TGFB2) Trabedersen (phase 3: cancer)
[16] Nucleocapsid protein (N) ALN-RSV01 (siRNA) (phase 2: RSV in lung
transplant patients)
[17] Myc (MYC) Resten-CP/Resten-NG (phases 2–3: restenosis)
[18] Protein kinase B alpha (Akt1) Archexin (phase 2: cancer)
[19] C-raf kinase (RAF1) iCo-007 (phase 2: diabetic macular edema)
[20] Spleen tyrosine kinase (STK) Excellair (siRNA) (phase 2: asthma)
[21] Connective tissue growth factor (CTGF) EXC-001 (phase 2: surgery-related ﬁbrosis)
[22] Integrin alpha 4 (ITGA4) ATL-1102 (phase 2: multiple sclerosis)
[23] P53 (TP53) Cenersen (phase 2: cancer)
[24] P53 (TP53) QPI-1002 (siRNA) (phase 2: prevention of delayed
graft function (kidney transplantation).
[25] DNA damage-inducible transcript 4 (DDIT4) PF-655 (siRNA) (phase 2: diabetic macular edema
and macular degeneration)
[26] Protein tyrosine phosphatase 1B (PTPN1) ISIS-113715 (phase 2: diabetes type 2)
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It induces ApoB mRNA degradation. It has been tested in
numerous clinical trials including phase 3 studies in which
efﬁcacy endpoints were met (9,10). The ﬁrst in-man
clinical trial showed rapid, dose-dependent long-term re-
duction of circulating ApoB of up to 50% (11). In recent
published accounts of phase 2 studies, as a single agent
and in combination with statins, the drug also showed
very efﬁcient target inhibition after treatment of patients
with a loading dose and then up to 400mg/week. This
resulted in lowered levels of LDL-cholesterol and trigly-
cerides (up to 71% and 53%, respectively, in one study
(12)) constituting clinical validation of the target (12–14).
The drug was well tolerated though there have been per-
sistent increases in transaminases, possibly due to pharma-
cologic inhibition of ApoB (15). It seems highly
improbable that mipomersen will face competition for
FH from any small-molecule drug if it were to gain
approval.
Dystrophin/eteplirsen, drisapersen for Duchenne
muscular dystrophy (DMD) [2,3]. Dystrophin is essential
for the normal function of skeletal and cardiac muscle. Its
gene is prone to mutations that result in muscular dystro-
phy (muscle weakening) (OMIM: 300377). DMD is
mostly due to DNA deletions which disrupt the reading
frame and produce a dysfunctional protein. High afﬁnity,
chemically modiﬁed ASOs can be designed to bind
sequence-speciﬁcally to pre-mRNA and induce ‘skipping’
of exons containing out-of-frame deletions leading to
accumulation of a shortened but nevertheless partially
functional protein. This concept was ﬁrst shown in cells
and has been validated in numerous examples in vivo (16).
The mechanism is now at the heart of a new therapeutic
strategy for the treatment of DMD using different se-
quences of fully modiﬁed morpholino (morpholino:
eteplirsen) and 20-O-methyl-phosphorothioate RNA
(drisapersen) oligonucleotides which induce exon
skipping in the dystrophin mRNA. In pioneering clinical
trials, treatments of DMD patients with eteplirsen and
drisapersen have led to restoration of the functional
target protein in high percentages of muscle ﬁbers
thereby validating the target (17). For example, in a
recently described phase 2 trial young participants
received eteplirsen by weekly intravenous infusions of
0.5–20mg/kg (18). Drug treatments were well tolerated
and increases in dystrophin (up to 16% by western blot)
and associated proteins were observed in muscle ﬁbers of
patients receiving the highest doses of drug. Newly
released data from a recent phase 2b trial demonstrated
‘unprecedented’ therapeutic beneﬁts from a once-weekly
treatment with eteplirsen at a dose of 50mg/kg for 36
weeks which resulted in an 70m beneﬁt in standard
6-min functional walk tests (http://investorrelations.
sareptatherapeutics.com/phoenix.zhtml?c=64231&p=
irol-newsArticle_print&ID=1717599&highlight; July
2012). In a phase 1-2a study of drisapersen treatment
of young patients, weekly subcutaneous injections of
0.5–6.0mg/kg of drug led to new dystrophin expression
through exon-51 skipping in all patients receiving the
two highest doses. All trial participants then received the
highest dose of drug in a 12-week extension phase result-
ing in a mean improvement of 35m in the functional walk
test (19). Once again, it seems highly improbable that
small-molecule drugs could be rationally designed to
restore the function of this genetically defective target,
though non-selective inducers of ribosomal read-through
of premature stop codons have been investigated
(reviewed in (17)).
B-cell leukemia-lymphoma gene 2 (Bcl-2)/oblimersen for
cancer [4]. Several late-stage oligonucleotide drugs have
been or are being investigated for treatment of cancers.
Three of the targets—clusterin, survivin, Bcl-2—have
well-characterized roles in mechanisms which protect
cancer cells from apoptosis induced by cytotoxic drugs.
The pro-survival factor Bcl-2 inhibits apoptosis and
enhances cell survival by inhibiting the release of cyto-
chrome c during apoptosis. Bcl-2 overexpression in
chronic lymphocytic leukemia (CLL) is associated with
aggressive disease and resistance to chemotherapy. Bcl-2
family members heterodimerize with pro-apoptotic regu-
lators and efforts to identify small-molecule drugs to
inhibit these protein–protein interactions have been
largely unsuccessful. One exception is the Bcl-2 antagonist
obatoclax mesylate. The drug is in clinical trials however
the results to date have not shown strong activity (20).
Oblimersen is a ﬁrst generation 18-mer phosphorothioate
oligodeoxynucleotide which potently down-regulates
Bcl-2, but also shows an antiproliferative effect through
the presence of immunostimulatory CpG motifs in its
sequence (21,22). Bcl-2 target downregulation by
oblimersen has been demonstrated in humans in several
clinical trials (reviewed in (23)). In one, oblimersen was
infused into young patients with solid tumors continu-
ously at 7mg/kg/day for several days in combination
with cytotoxics. Reduced Bcl-2 expression was observed
in peripheral blood mononuclear cells (PBMCs) in many
of the patients before administration of the cytotoxics: in
Figure 1. Structures of chemically modiﬁed oligonucleotides in Table 1. (I) Phosphorothioate oligodeoxyribonucleotide; (II) 20-O-methyl-
ribonucleotide (20-O-Me); (III) 20-O-methoxyethyl (MOE)-ribonucleotide; (IV) LNA; and (V) Morpholino nucleotide analog.
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half of these cases reductions were to below 50% of
pre-treatment levels (24). In another phase 1 combination
trial of oblimersen in acute leukemia patients levels of
Bcl-2 transcripts were measured in bone marrow cells of
12 patients after 5 days of treatment, prior to chemother-
apy (25). Target downregulation of up to 76% was seen in
75% of the patients and in some of these cases, suppres-
sion of Bcl-2 protein of 80% was also seen by immuno-
blotting. In yet another phase 1 study in elderly AML
patients administered with oblimersen and cytarabine, or
daunorubicin investigators found that those patients with
a complete remission (48%) experienced decreased Bcl-2
mRNA and protein levels in bone marrow samples after
72 h of drug infusion and prior to chemotherapy whereas,
increased Bcl-2 was seen in the non-responders (26).
Clinical trials with oblimersen have spanned more than
10 years. Although some of which have shown survival
advantages for patients this drug remains unapproved.
Survivin/LY2181308 for cancer [5]. Survivin is a member
of the Inhibitors of apoptosis (IAP) family. In cells, it
functions as a stress-induced cytoprotective chaperone
exerting its anti-apoptotic effects through binding to the
second mitochondrial activator of caspases (SMAC)
(reviewed in (27)). It is highly expressed in many human
cancer types, but not in differentiated tissues, and is
associated with poor prognosis. LY2181308 (ISIS-23722)
is an 18-mer ASO modiﬁed with terminal 20-O-(MOE)
ribonucleotides which targets the translation initiation
codon of survivin. An account of a ﬁrst in-human dose
study described how the drug was delivered intravenously
as a saline solution initially daily for 3 days as a loading
dose and then up to 750mg weekly into cancer patients.
Survivin mRNA and protein in a wide range of tumor
tissues were both reduced by 20% and the apoptosis
marker CC3 indicated restored apoptosis, thereby
validating the clinical rationale (28). Positron emission
tomography (PET) conﬁrmed that the drug accumulated
in solid tumor tissue, as well as kidney and liver (29). No
objective responses were seen in these patients and the
investigators have speculated that this might be due to
an insufﬁcient target downregulation in tumor tissue.
The focus now is use of LY2181308 in combination with
chemotherapy or radiation. While survivin can be classi-
ﬁed as undrugable, in the event of successful development,
LY2181308 may face competition from YM155, a
small-molecule inhibitor of survivin transcription (30).
Clusterin/custirsen for cancer [6]. Clusterin is a
stress-induced, cytoprotective small heat-shock chaperone
protein. It is expressed in virtually all tissues and is
secreted. In cancer clusterin inhibits apoptosis through
its suppression of proapoptotic BAX and activates the
PI3K/AKT cell survival pathway (reviewed in (31)).
Clusterin levels are increased in a variety of cancers with
broad-spectrum resistance to radiation and chemotherapy
and inhibition of clusterin enhances apoptosis in xenograft
models of cancer. Custirsen (OGX-011) is a 21-mer
MOE-modiﬁed ASO targeting the clusterin mRNA
AUG translation initiation site. The ﬁrst in-man phase 1
dose-determining study of custirsen was performed in 25
patients with localized prostate cancer using up to 640mg
of intravenously administered ASO, combined with
androgen blockade (32). Treatment was well tolerated.
Clusterin expression was assayed before and after drug
treatment in prostatectomy, as well as in lymph nodes
and PBMCs as surrogate tissues. Quantitative reverse
transcriptase PCR (Q-PCR) and immunohistochemistry
(IHC) showed a very efﬁcient dose dependent inhibition
of clusterin mRNA (>90% at the maximum dose) and
protein (complete suppression in 57% of cells at the
maximum dose) in prostate cancer tissue. This correlated
with increasing levels of the drug in prostate cancer tissue
measured by ELISA. At the highest dose, the apoptotic
index in prostatectomy specimens was increased thereby
validating the clinical hypothesis. Downregulation of
serum clusterin by 40% was documented in a second
phase 1 trial (33). This drug progressed into phase 2
clinical trials for various cancers in combination with
cytotoxics (34–36). These trials have shown promise for
patients in terms of median survival (33) or time to disease
progression. Although clusterin is probably undrugable to
small-molecule drugs, its validation as a target by
custirsen may result in competition from biologics, for
example the antibody AB-16B5 or the peptide
CGEN-25008.
Hsp27/OGX-427 for cancer [7]. Heat Shock 27 kDa
Protein 1 (Hsp27) is another small heat shock protein
under clinical investigation as a target for cancer treat-
ment using a MOE-modiﬁed ASO. It is highly expressed
in several types of cancer: in castration-resistant prostate
cancer (CRPC) its expression is induced by androgen
removal and/or chemotherapy. It inhibits the activation
of caspases as well as activating STAT3 and AKT onco-
genic pathways. It is therefore an attractive target in
cancer however it is undrugable with small molecules.
OGX-427 is a 20-mer MOE ASO which has completed
single agent and combination phase 1 trials to determine
dose in prostate, bladder, as well as breast and lung
cancer. Reduction of tumor markers in prostate
(prostate-speciﬁc antigen (PSA): >40% reduction in 3
from 16 patients) and ovarian (cancer-antigen 125:
>20% reduction in 3 from 5 patients) cancers was report-
edly observed in patients, as well as decreased numbers of
circulating tumor cells and lowered Hsp27 expression
measured by immunoﬂuorescence (37,38).
EIF-4E/LY2275796 for cancer [8]. The expression of the
mRNA cap binding protein eukaryotic initiation factor 4E
(EIF-4E) is often upregulated in tumors (39). A 20-mer
MOE-ASO (LY2275796) was developed to inhibit EIF-4E
and tested in a phase 1 dose ﬁnding trial in patients with
advanced solid tumors (40). The ASO was administered
intravenously in a loading dose over 3 days and then at
weekly infusions up to 1000mg doses. PK parameters
were determined from plasma samples using an ELISA
to detect the drug. Target downregulation was assessed
by comparing EIF-4E mRNA expression and protein
IHC from pre- and post-treatment tumor biopsy
samples. In 75% of the patients receiving the 1000mg
dose a reduction in target protein expression was seen,
and in 6 from 7 cases an 80% inhibition of target
mRNA was measured. Two tumor-promoting proteins
regulated by EIF-4E—VEGF and cyclin D1—were also
reduced. The treatment was well tolerated however no
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tumor responses were observed at the doses at which
target inhibition was achieved. The investigators suggested
that the ASO be pursued in combination studies, but at
the same time they also cautioned that EIF-4E may not be
a valid target.
RNR/GTI-2040 for cancer [9]. Overexpression of
ribonucleotide reductase (RNR), an enzyme composed
of R1 and R2 subunits which converts ribonucleosides
to deoxyribonucleosides, is commonly observed in
cancer cells. It increases levels of deoxynucleosides,
thereby competing with nucleoside cytotoxics and
providing a mechanism of chemoresistance. RNR has
been validated as a target in cancer using small-molecule
drugs however selectivity issues with such compounds
have been reported (41,42). Increased cellular levels of
RNR reduce the effectiveness of nucleoside anticancer
drugs such as cytarabine (AraC), a cytidine derivative
which is incorporated into and halts DNA synthesis (see
references in (43)). GTI-2040 is a ﬁrst generation 20-mer
phosphorothioate oligodeoxynucleotide which inhibits the
R2 subunit (RRM2). This creates an imbalance in cellular
levels of cytidine triphosphate and favors incorporation
of AraC into DNA. GTI-2040 has been tested in a
handful of phase 1 and phase 1/2 trials, as a single agent
and in combination. As with other phosphorothioate
oligodeoxynucleotides the drug has a short plasma
half-life and is continuously infused into patients over
several days. Target downregulation was seen in a phase
2 trial of GTI-2040 in white blood cells and tumor tissue
assayed from a single patient before and after drug treat-
ment (44). A strong suppression (25-fold decrease) of the
target mRNA was seen providing conﬁrmation of delivery
of the drug to tumor tissue. In a dose escalation phase 1
trial, patients with acute myeloid leukemia (AML) were
infused intravenously with GTI-2040 prior to exposure to
high doses of AraC (43). Levels of GTI-2040 were
measured in plasma and the lysates of bone marrow
cells after initiation of infusion. R2 protein expression
was measured pre- and post-treatment in bone marrow
cells at the same time-points. A trend for preferred
uptake of oligonucleotide into leukemic cells was
observed and drug concentrations in cells increased
2-fold over the measurement time-period. Furthermore,
reductions of R2 protein to >50% were seen in the bone
marrow samples from some patients. Complete remission
was associated with a signiﬁcant reduction in target
protein levels, whereas non-responders showed increased
levels. A phase 2 study of GTI-2040 in combination with
docetaxel and prednisone in CRPC was less encouraging
(45): continuous infusion over 14 days of drug led to a
PSA response in less than half of the patients. The trial
was not extended with the investigators citing insufﬁcient
dosing to achieve target downregulation, difﬁculties to
deliver intravenous dosing for 14 continuous days and
doubts concerning the relevance of the target for CRPC.
CCR3, c chain/TPI ASM8 for asthma [10]. Eosinophils
play an important pathogenic role in allergic asthma. The
late asthmatic response (LAR) to inhaled allergen chal-
lenge induces the proliferation and migration of eosino-
phils. This depends upon chemokine signaling involving
C-C chemokine receptor type 3 (CCR3) and the
stimulation of receptors for the cytokines IL-3, IL-5 and
granulocyte-macrophage colony-stimulating factor
(GM-CSF) comprising a common beta chain (c).
Indeed, IL-5 has been proposed as an important drug
target for allergy and associated disorders (reviewed in
(46)) and at least two antibodies against the IL-5
cytokine and its receptor are in clinical testing. The drug
product TPI ASM8 comprises two ﬁrst generation 19-mer
phosphorothioate oligodeoxynucleotides (adenines in the
sequence are replaced with 20-amino-20-deoxyadenine)
directed to CCR3 and the common c. By targeting
multiple factors possibly playing redundant roles in the
disease, a highly effective response was anticipated in
patients. In one clinical trial, patients with mild atopic
asthma were treated by nebulizer with 1.5mg per day of
drug over 4 days (47). A signiﬁcant reduction in early
asthmatic response (EAR) and a trend for reduced LAR
were reported. Target mRNA inhibition was monitored in
sputum samples. Drug uptake into the cells was monitored
by hybridization ELISA. TPI ASM8 inhibited the increase
in sputum eosinophils induced by the allergen. In six of the
eight patients assayed, target mRNA levels were lowered.
Although suppressed cell surface protein of CCR3 or c
was not conﬁrmed, the authors suggest that this may be
due to analysis of inappropriate cell types. Results of a
second trial have since emerged with similar results
(48,49). Drug treatment was safe and well tolerated:
dose response was reported and efﬁcacy was maintained
with one administration per day suggesting clinical valid-
ation of the target and showing promise for the drug.
ICAM1/alicaforsen for pouchitis [11]. Intercellular
adhesion molecule-1 (ICAM1) is a transmembrane glyco-
protein expressed in endothelial cells and leukocytes. It
facilitates leukocyte migration from blood to sites of
inﬂammation and is involved in inﬂammatory bowel
pathophysiology. Inﬂammatory bowel disease (IBD)
encompasses an array of disorders including Crohn’s
disease (CD) and ulcerative colitis (UC). ICAM1 was
selected as a target for IBD because of its role in cell
trafﬁcking, because it is present during intestinal inﬂam-
mation and because increasing levels of circulating protein
are observed in patients with CD, UC and pouchitis.
Alicaforsen is a 20-mer phosphorothioate oligodeoxy-
nucleotide targeted to ICAM1. Several clinical trials of
alicaforsen have been completed (reviewed in (50)).
Clinical trials of intravenously delivered drug in patients
with CD failed to show a signiﬁcant effect on disease,
although intestinal biopsy samples from patients in one
of the trials showed reduced levels of intestinal mucosal
ICAM1 expression in the majority of the patients given
the highest 2mg/kg drug dose (51). It has since been sug-
gested that some of the patients selected for these CD
trials did not in fact have CD, but rather irritable bowel
syndrome, contributing to the failed trial outcomes (52).
Alicaforsen was delivered as an enema for UC in larger
clinical trials and has demonstrated some reduction in
disease activity in the long term (53), but the most
promising data have been obtained in treatment of
pouchitis. In a small open-label trial of alicaforsen the
drug was shown to be safe and well tolerated (54). The
results from nightly enema formulations of up to 240mg
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administered for 6-weeks were evaluated by endoscopy
during the treatment and 4 weeks following treatment.
Overall a statistically signiﬁcant reduction in pouchitis
disease activity index was observed and 58% of patients
were in remission, and trials were considered very
promising (reviewed in (50)). Interestingly, longer-term
beneﬁts were unexpectedly observed in many patients
and the investigators have called for further trials not
only to evaluate alicaforsen as a drug, but also to
validate ICAM1 as an effective target in the inﬂammatory
pathway.
C-Reactive protein/ISIS-CRPRx for cardiovascular
disorder [12]. C-reactive protein (CRP) is produced in
the liver and increased levels of the protein are seen in a
variety of disorders including cardiovascular disease,
diabetes and various inﬂammatory conditions.
ISIS-CRPRx is a MOE ASO which recently completed a
phase 1 clinical trial in 80 subjects at single and multiple
doses from 50–600mg/week (http://ir.isispharm.com/
phoenix.zhtml?c=222170&p=irol-newsArticle_pf&ID=
1531705; February 2011). An average reduction of more
than 70% in circulating CRP was reported. The drug
sponsors have announced that this ﬁrst CRP inhibitor
will be employed as an early proof of concept for the
target in a variety of diseases, including multiple
myeloma and rheumatoid arthritis.
TTR/ALN-TTR02 for amyloidosis [13]. We identiﬁed
ﬁve siRNAs in phase 2 clinical trials ([13], [16], [20], [24],
[25]). From these, target suppression has only been
reported for one—ALN-TTR02, though a working
RNAi mechanism in man was shown for a formulated
siRNA whose development has since been discontinued
(55). The hereditary form of amyloidosis, ATTR
(OMIM: 176300) is caused by mutations in the
transthyretin gene (TTR), which is expressed predomin-
antly in the liver, and results in the accumulation of patho-
genic deposits of mutant and wild-type TTR protein in
multiple extra-hepatic tissues, including the peripheral
nervous system and heart. The intravenously adminis-
tered, lipid nanoparticle (LNP)-formulated chemically un-
modiﬁed siRNA ALN-TTR02 targets the mutant TTR
protein responsible for TTR-mediated amyloidosis.
Recently this siRNA has progressed into phase 2 trials
following promising phase 1 results in which the drug
was well tolerated and demonstrated an up to 94% reduc-
tion in serum TTR levels in healthy volunteers after a
single dose (0.01–0.50mg/kg) (http://phx.corporate-ir
.net/phoenix.zhtml?c=148005&p=irol-newsArticle_print
&ID=1714793&highlight; July 2012). Furthermore, TTR
downregulation was reportedly sustained at up to 80% 1
month after treatment ceased.
Miscellaneous drug/target combinations not reporting
target inhibition. Many of the oligonucleotide drugs in
advanced clinical trials reportedly have positive effects in
patients but, for a variety of possible reasons, the PD data
describing inhibition of target by the drug has not been
reported (Table 1, [14–26]). Miravirsen (SPC-3649: (14)) is
a 15-mer locked nucleic acid (LNA)-modiﬁed phospho-
rothioate oligodeoxynucleotide ASO. The LNA modiﬁca-
tion, interspersed throughout an oligodeoxyribonucleotide
sequence, endows the molecule with nuclease stability and
high afﬁnity for its target, the host liver-speciﬁc miRNA
mir-122, which it sequesters in a duplex structure thereby
blocking its function without inducing its degradation.
Mir-122 is highly conserved across several species and
regulates lipid metabolism. However, it also interacts at
adjacent sites in the 50 terminus of the hepatitis C viral
(HCV) RNA, resulting in increased viral RNA abundance
by a poorly understood mechanism. Miravirsen has shown
long-lasting suppression of HCV viremia in chronically
infected chimpanzees and is the ﬁrst anti-miRNA drug
to enter the clinic. Weekly subcutaneous injections of the
drug at up to 7mg/kg have strongly reduced HCV RNA in
patients, in one case to undetectable levels after 1 month
(56). Circulating levels of cholesterol, ApoA and ApoB
have served as efﬁcacy biomarkers for the drug.
Trabedersen (AP12009: [15]) is a 20-mer ﬁrst generation
phosphorothioate oligodeoxynucleotide targeting TGF-b2
mRNA in phase 3 clinical trials. The drug has generated
promising data in numerous clinical trials for the treat-
ment of malignant brain cancers after local delivery
directly into tumors (reviewed in (57)) however, correl-
ation of the anti-tumor activity with target downregu-
lation has not yet been reported (58).
To date, target inhibition has not been reported for the
majority of the siRNAs in clinical trials, partly reﬂecting
the younger status of this ﬁeld. One of the most clinically
advanced siRNAs is the intranasally administered siRNA
ALN-RSV-01 [16] which targets the nucleocapsid protein
of respiratory syncytial virus (RSV), a structural protein
responsible for encapsidation of the viral genome. This
siRNA is an unmodiﬁed 19-mer RNA phosphorodiester
duplex with 30-overhangs of thymidine deoxynucleotides.
In phase 1 trials it proved to be safe and well tolerated in
healthy subjects (59) and in experimentally infected volun-
teers ALN-RSV-01 treatment prevented RSV infection
(60). In lung transplant patients with RSV infections it
reduced symptoms and the incidence of new or progressive
bronchiolitis obliterans syndrome caused by the infections
(61). A larger trial is ongoing.
DISCUSSION
Properly designed oligonucleotides are speciﬁc inhibitors
of gene expression. They are well suited to the modern
paradigm of pharmaceutical research which begins with
the gene coding for a disease-relevant target. Where a
target represents a new mechanism of action and is
being investigated for the ﬁrst time in patients there is a
steep learning curve and a high probability of failure (6).
We examined 26 oligonucleotide drug/target combin-
ations which are, or were recently, in phase 2 clinical
trials or above according to the Thomson Reuters
Integrity database (Table 1). In at least 14 cases down-
regulation of target mRNA or protein levels in the
relevant tissues/cell types in patients has been described
in publications or company web-releases, conﬁrming
that the drugs were able to reach their targets in liver,
muscle ﬁbers, various solid tumors, lymph nodes, bone
marrow, eosinophil progenitors, blood cells and intestinal
mucosa. Thirteen of these cases involved single-stranded
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oligonucleotides, and in none was a formulation used to
enhance delivery. The sole siRNA in the group was ad-
ministered in a LNP-formulation.
For the less metabolically stable, ﬁrst generation
phosphorothioate oligodeoxyribonucleotides local admin-
istration has been a favored form of delivery. The ﬁrst
therapeutic ASO to be approved, fomiversen, was a full
phosphorothioate oligodeoxyribonucleotide targeting the
viral IE2 gene of human cytomegalovirus which was ad-
ministered by intravitreal injection (62). A local delivery
was also employed for four of the drugs discussed above:
TPI ASM8 (pulmonary administration), alicaforsen
(enema), trabedersen (intracranial infusion) and the
siRNA ALN-RSV-01 (pulmonary administration). In
the remainder of the cases the drug is delivered intraven-
ously by infusion or subcutaneously. For the ﬁrst gener-
ation phosphorothioate oligodeoxyribonucleotides
GTI-2040 and oblimersen the drug infusions continued
over many days, in some cases causing technical
difﬁculties (45). For the second generation molecules
(MOE, morpholino, LNA) it was sufﬁcient to administer
drug doses weekly. This may reﬂect greater serum stability
of the second generation molecules which, together with
their added potency, is a tribute to extensive research on
modiﬁcation of the ribose by medicinal chemists (63–66).
In vivo, drugs need to cross numerous biological barriers
to reach their targets (reviewed in (8,67)). After systemic
administration single-stranded phosphorothioate oligo-
nucleotides circulate non-covalently bound to plasma
proteins which, because of their size, slow down their
renal ﬁltration and clearance. In this form they are also
protected from nuclease degradation. They pass across the
vascular endothelial barrier and diffuse through the extra-
cellular matrix to distribute broadly in the body, particu-
larly to liver, adipose tissue, spleen, kidney, bone, bone
marrow, intestine and macrophages. The oligonucleotides
transverse plasma membranes of cells possibly by
receptor-mediated endocytosis to reach the cytoplasm in
vesicles, though receptors responsible for cellular entry
have not been characterized. Intracellular trafﬁcking into
endosomes and/or lysosomes follows, and the oligo-
nucleotides can escape in small amounts from some of
these compartments in order to access their RNA targets
in the cytoplasm and the nucleus. The mechanisms
of intracellular trafﬁcking are poorly understood and are
the subject of ongoing research. Strong pharmacokinetic/
pharmacodynamic (PK/PD) relationships—where the dis-
tribution of the drug correlates with its observed
activity—have been established in the liver and the
kidney cortex in mice for both phosphorothioate
oligodeoxynucleotides and MOE-modiﬁed oligonucleo-
tides (68). However, clinical PK/PD relationships require
predictive PK and reliable PD biomarkers, therefore com-
paratively few PK/PD relationships for oligonucleotide
drugs in man have been described. From the drugs high-
lighted above, strong clinical PD/PK relationships were
demonstrated for custirsen in prostate cancer and for
mipomersen.
Target selection is a critical phase in drug discovery,
particularly for oligonucleotide drugs. Decreasing prod-
uctivity in pharma R&D has cast doubts on the modern
paradigm of pharmaceutical research that begins with a
target gene: many successful drugs originally discovered
by compound proﬁling modulate multiple targets and it
is recognized that drug targets often have redundancy
pathways (69), limiting the choice of targets for a
gene-speciﬁc approach. In addition, it is preferable that
oligonucleotide drugs do not face competition with
cheaper mainstream drugs for the same target. This is
achieved by working outside of the drugable genome on
novel mechanisms; however, the risk of project failure is
increased.
Most of the 26 targets of Table 1 represent new mech-
anistic targets. Three of the targets from Table 1 (APOB,
DMD, TTR) are genetically validated: mutations in the
DNA sequence of the gene cause the disease. For APOB
and DMD, second generation ASOs (mipomersen,
eteplirsen, drisapersen) have shown the expected effects
on the target protein in patients in multiple clinical
trials. In turn, this has yielded improvements in disease
thereby providing clinical validation of the targets. A
subset of the targets (BCL2, CLU, HSPB1, BIRC5,
EIF4E and RRM2) is being investigated for cancers in
combination with approved cytotoxic drugs. Varying
degrees of target mRNA and protein inhibition by oligo-
nucleotides have been observed in tumor tissues in
patients and in many cases this has been associated with
anti-tumor activity, However, the general lack of robust
effects on disease outcome seen so far leads some investi-
gators to question whether it is insufﬁcient target inhib-
ition due to sub-optimal drug delivery or an invalid target
which is to blame (40,70). As small-molecule inhibi-
tors of several of these targets (obatoclax/BCL2 (20),
gemcitabine/RNR (45) and YM155/survivin (30)) have
also yet to be successful, the validity of the targets may
indeed be suspect. It is to be expected that many of the
drugs described here will eventually be withdrawn from
development. Although detailed information concerning
the reasons for failure is often not publicly available,
poor drug tolerability and insufﬁcient target inhibition
will likely be responsible for some of these cases, traits
that are often associated with use of ﬁrst generation
phosphorothioate oligodeoxynucleotides. In other cases
however, as we emphasize here, inefﬁcient target delivery,
inappropriate disease target selection, sub-optimal trial
design and patient selection may all contribute to unsuc-
cessful outcomes.
Oligonucleotide drugs still represent a promising
new paradigm in drug discovery/development. Emerging
data have conﬁrmed that they are delivered to many
organs/tissues at concentrations sufﬁcient to inhibit their
RNA targets and see therapeutic effects in man. New
robust methods of, for example, LNP-formulated
delivery to currently inaccessible tissues may expand
their application further, once associated issues of
toxicity, manufacturing complexity and cost have been
solved. Although in principle, oligonucleotides can be
targeted to any gene of the genome, in reality, they will
likely be most successful when targeting genes in new
mechanisms outside of the drugable genome and in mono-
genic diseases.
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